Indivior Pharmaceuticals (INDV) Interest Expenses (2024 - 2026)

Indivior Pharmaceuticals' Interest Expenses history runs 3 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 41.67% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at $40.0 million (down 11.11% YoY), while the FY2025 annual figure was $45.0 million, up 9.76% from the prior year.
• Interest Expenses was $7.0 million for Q1 2026 at Indivior Pharmaceuticals, up from $6.0 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $15.0 million in Q2 2025 to a low of $6.0 million in Q4 2025.
• Historically, Interest Expenses has averaged $10.4 million across 3 years, with a median of $11.0 million in 2024.
• Biggest YoY gain for Interest Expenses was 66.67% in 2025; the steepest drop was 53.85% in 2025.
• A 3-year view of Interest Expenses shows it stood at $13.0 million in 2024, then plunged by 53.85% to $6.0 million in 2025, then gained by 16.67% to $7.0 million in 2026.
• The last three Interest Expenses figures came in at $7.0 million (Q1 2026), $6.0 million (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.